Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.31 |
| ▸ | GAA | P10253 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313709 | 0.82 | CHRNB2 (0.38) | CHRNB2CHRNA4KMT2AMEN1AHR | |
| SCHEMBL2371062 | 0.79 | CHRNB2 (0.36) | CHRNB2CHRNA4KMT2AMEN1AHR | |
| SCHEMBL31523267 | 0.75 | MAPK1 (0.41) | KMT2AMEN1ALDH1A1GAAHTT | |
| SCHEMBL16187963 | 0.74 | ALDH1A1 (0.36) | CHRNB2CHRNA4ALDH1A1GAAKCNQ3 | |
| SCHEMBL30749766 | 0.73 | TSHR (0.43) | AHRALDH1A1GAA | |
| SCHEMBL2669593 | 0.73 | TSHR (0.43) | AHRALDH1A1GAA | |
| SCHEMBL20772451 | 0.72 | MEN1 (0.46) | KMT2AMEN1AHRPOLB | |
| SCHEMBL29987444 | 0.71 | TSHR (0.42) | AHRALDH1A1GAA | |
| SCHEMBL26383745 | 0.70 | PIK3CA (0.46) | ALDH1A1 | |
| SCHEMBL25604920 | 0.70 | ALDH1A1 (0.43) | KMT2AMEN1ALDH1A1HTTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | CHRNB2 1431/4885CHRNA4 1139/4885KMT2A 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.